AXA cut its position in shares of Oxford Immunotec Global PLC (NASDAQ:OXFD) by 1.4% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 882,157 shares of the company’s stock after selling 12,231 shares during the period. AXA owned approximately 3.44% of Oxford Immunotec Global worth $14,820,000 at the end of the most recent quarter.
A number of other hedge funds have also recently modified their holdings of OXFD. Perceptive Advisors LLC raised its stake in shares of Oxford Immunotec Global by 955.1% in the 3rd quarter. Perceptive Advisors LLC now owns 465,356 shares of the company’s stock valued at $7,818,000 after acquiring an additional 421,250 shares during the period. Alyeska Investment Group L.P. raised its stake in shares of Oxford Immunotec Global by 44.0% in the 3rd quarter. Alyeska Investment Group L.P. now owns 1,355,529 shares of the company’s stock valued at $22,773,000 after acquiring an additional 413,904 shares during the period. RTW Investments LP raised its stake in shares of Oxford Immunotec Global by 21.9% in the 3rd quarter. RTW Investments LP now owns 1,032,370 shares of the company’s stock valued at $17,344,000 after acquiring an additional 185,453 shares during the period. Stonepine Capital Management LLC purchased a new stake in shares of Oxford Immunotec Global in the 3rd quarter valued at approximately $2,726,000. Finally, Columbus Circle Investors purchased a new stake in shares of Oxford Immunotec Global in the 3rd quarter valued at approximately $2,640,000. 89.35% of the stock is currently owned by institutional investors.
Shares of Oxford Immunotec Global PLC (NASDAQ:OXFD) traded up $0.47 during mid-day trading on Thursday, hitting $11.98. 299,785 shares of the company were exchanged, compared to its average volume of 415,573. The company has a quick ratio of 4.30, a current ratio of 4.72 and a debt-to-equity ratio of 0.38. The firm has a market capitalization of $307.34, a PE ratio of -5.96 and a beta of -0.09. Oxford Immunotec Global PLC has a 52-week low of $10.81 and a 52-week high of $19.51.
In related news, Director Richard A. Sandberg sold 3,000 shares of Oxford Immunotec Global stock in a transaction that occurred on Wednesday, November 1st. The shares were sold at an average price of $13.35, for a total value of $40,050.00. Following the completion of the transaction, the director now owns 17,778 shares in the company, valued at $237,336.30. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 8.11% of the company’s stock.
A number of equities research analysts have recently issued reports on OXFD shares. BidaskClub downgraded shares of Oxford Immunotec Global from a “hold” rating to a “sell” rating in a research note on Saturday, December 9th. BTIG Research set a $21.00 price target on shares of Oxford Immunotec Global and gave the company a “buy” rating in a research note on Monday, December 18th. Piper Jaffray Companies dropped their price objective on shares of Oxford Immunotec Global from $26.00 to $19.00 and set an “overweight” rating for the company in a report on Tuesday, October 31st. Zacks Investment Research cut shares of Oxford Immunotec Global from a “hold” rating to a “sell” rating in a report on Saturday, November 4th. Finally, Robert W. Baird restated a “buy” rating and issued a $20.00 price objective on shares of Oxford Immunotec Global in a report on Wednesday, November 1st. Three investment analysts have rated the stock with a sell rating and four have issued a buy rating to the company. Oxford Immunotec Global has an average rating of “Hold” and an average price target of $19.75.
TRADEMARK VIOLATION NOTICE: “Axa Has $14.82 Million Holdings in Oxford Immunotec Global PLC (OXFD)” was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this article on another website, it was stolen and reposted in violation of international copyright & trademark legislation. The legal version of this article can be accessed at https://www.dispatchtribunal.com/2018/01/11/axa-has-14-82-million-holdings-in-oxford-immunotec-global-plc-oxfd.html.
Oxford Immunotec Global Company Profile
Oxford Immunotec Global PLC is a diagnostics company. The Company is focused on developing and commercializing tests for under-served immune-regulated conditions. The Company’s product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology.
Receive News & Ratings for Oxford Immunotec Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global and related companies with MarketBeat.com's FREE daily email newsletter.